Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil
- PMID: 29650385
- DOI: 10.1016/j.vaccine.2018.04.010
Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil
Abstract
Background: In March 2010, the 10-valent pneumococcal conjugate vaccine (PCV10) was introduced into the routine immunization program in Brazil. We describe the pneumococcal serotypes that caused invasive pneumococcal diseases (IPD) before and after the introduction of PCV10 using data from a national laboratory-based surveillance system.
Method: We compared the prevalence of vaccine types (VT) and non-vaccine types (NVT) of Streptococcus pneumoniae in three periods, pre-PCV10 (January/2005-December/2009), early post-PCV10 (January/2010-December/2013), and late post-PCV10 (January/2014-December/2015), by episode in meningitis and non-meningitis cases and by age group. Changes in serotype prevalence in the early and late post-PCV10 periods were determined using pre-PCV10 period as a reference.
Results: A total of 8971 IPD isolates from patients aged 2 months to 99 years were analyzed. In the late post-PCV10 period, the VT-IPD reduction in the 2-month to 4-year age group was 83.4% for meningitis and 87.4% for non-meningitis cases; in the age groups 5-17 years, 18-64 years, and ≥65 years, VT declined by 56.1%, 54.1%, and 47.4%, respectively, in meningitis cases, and by 60.9%, 47.7%, and 53.4%, respectively, in non-meningitis cases. NVT-IPD increased throughout the study period, driven mainly by serotypes 3, 6C, and 19A, which remained the predominant types causing IPD in the late post-PCV10 period.
Conclusion: We observed direct and indirect PCV10 protection against IPD caused by VT and a shift in the distribution of serotypes 5 years after the introduction of PCV10. Continued IPD surveillance is needed to evaluate the sustainability of the high prevalence of serotypes 3, 6C, and 19A, which were not included in PCV10.
Keywords: 10-valent pneumococcal conjugate vaccine; Pneumococcal conjugate vaccine; Pneumococcal serotypes; Streptococcus pneumoniae.
Copyright © 2018 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
A decade of 10-valent pneumococcal conjugate vaccine use in Lithuania: trends in invasive pneumococcal serotype dynamics.Front Public Health. 2025 Aug 1;13:1633396. doi: 10.3389/fpubh.2025.1633396. eCollection 2025. Front Public Health. 2025. PMID: 40823216 Free PMC article.
-
Pneumococcal serotype evolution in Western Europe.BMC Infect Dis. 2015 Oct 14;15:419. doi: 10.1186/s12879-015-1147-x. BMC Infect Dis. 2015. PMID: 26468008 Free PMC article. Review.
-
Long-term surveillance of invasive pneumococcal disease: The impact of 10-valent pneumococcal conjugate vaccine in the metropolitan region of Salvador, Brazil.Vaccine. 2024 Jan 25;42(3):591-597. doi: 10.1016/j.vaccine.2023.12.055. Epub 2024 Jan 5. Vaccine. 2024. PMID: 38184393 Free PMC article.
-
Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in São Paulo, Brazil.Vaccine. 2016 Nov 4;34(46):5604-5611. doi: 10.1016/j.vaccine.2016.09.027. Epub 2016 Sep 28. Vaccine. 2016. PMID: 27692770
-
A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children.Expert Rev Vaccines. 2022 Feb;21(2):201-214. doi: 10.1080/14760584.2022.2012455. Epub 2022 Feb 3. Expert Rev Vaccines. 2022. PMID: 34882050
Cited by
-
Impact after 10-year use of pneumococcal conjugate vaccine in the Brazilian national immunization program: an updated systematic literature review from 2015 to 2020.Hum Vaccin Immunother. 2022 Dec 31;18(1):1879578. doi: 10.1080/21645515.2021.1879578. Epub 2021 Mar 18. Hum Vaccin Immunother. 2022. PMID: 33735585 Free PMC article.
-
Global distribution and characteristics of pneumococcal serotypes in adults.Hum Vaccin Immunother. 2025 Dec;21(1):2469424. doi: 10.1080/21645515.2025.2469424. Epub 2025 Feb 27. Hum Vaccin Immunother. 2025. PMID: 40015240 Free PMC article. Review.
-
[Regional System for Vaccines (SIREVA), laboratory surveillance and vaccine development for Streptococcus pneumoniae: bibliometric analysis, 1993-2019].Rev Panam Salud Publica. 2020 Aug 6;44:e80. doi: 10.26633/RPSP.2020.80. eCollection 2020. Rev Panam Salud Publica. 2020. PMID: 32774349 Free PMC article. Spanish.
-
Routine infant vaccination of pneumococcal conjugate vaccines has decreased pneumonia across all age groups in Northern Spain.Hum Vaccin Immunother. 2020 Jun 2;16(6):1446-1453. doi: 10.1080/21645515.2019.1690884. Epub 2019 Dec 18. Hum Vaccin Immunother. 2020. PMID: 31851569 Free PMC article.
-
Safety and efficacy of an intramuscular bivalent vaccine against influenza and Streptococcus pneumoniae infections in mice.Med Microbiol Immunol. 2025 Aug 29;214(1):39. doi: 10.1007/s00430-025-00848-w. Med Microbiol Immunol. 2025. PMID: 40879808
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical